Taconic Biosciences Acquires TransCure bioServices

Eclipsebio Acquires Terrain Bio

January 29, 2026

Biotechnology

Eclipse Bioinnovations (Eclipsebio) has acquired Terrain Bio to integrate Terrain's AI/ML RNA design models and R&D-scale mRNA manufacturing analytics into Eclipsebio's sequencing-based validation platforms. The deal creates an end-to-end Design, Make, Test platform intended to accelerate RNA therapeutic development by connecting computational design directly to experimental feedback.

Tome Biosciences Acquires Replace Therapeutics

January 5, 2024

Biotechnology

Tome Biosciences has acquired Replace Therapeutics in a merger valued at $65 million in up-front and near-term milestones and up to $185 million total through a mix of cash and stock. Replace will become a wholly owned subsidiary of Tome, adding its ligase-mediated programmable genomic integration (L-PGI) technology to complement Tome's large-DNA integrase-mediated PGI platform to expand the company's gene‑editing capabilities.

Avista Capital Partners Acquires Taconic Biosciences

November 1, 2022

Biotechnology

Avista Capital Partners has acquired Taconic Biosciences from H.I.G. Capital. Taconic, a Rensselaer, New York–based provider of genetically engineered murine research models and related preclinical services, will leverage Avista's healthcare investing expertise to pursue organic growth and strategic acquisitions in the GEMs market.

Sanofi Acquires Translate Bio in $3.2 Billion Deal

August 3, 2021

Biotechnology

Sanofi SA has entered into a definitive agreement to acquire all outstanding shares of clinical-stage mRNA therapeutics company Translate Bio for about $3.2 billion, or $38.00 per share in cash. The acquisition is intended to accelerate Sanofi’s application of messenger RNA (mRNA) to develop therapeutics and vaccines, building on an existing mRNA collaboration.

Charles River Laboratories Acquires Cognate BioServices

February 17, 2021

Biotechnology

Charles River Laboratories agreed to acquire Cognate BioServices for approximately $875 million in cash, expanding Charles River's capabilities into the high-growth cell and gene therapy CDMO sector. Cognate, headquartered in Memphis, Tennessee with over 500 employees, will provide Charles River integrated cell and gene therapy development, testing, and CGMP manufacturing capabilities; the deal was expected to close by end of Q1 2021.

H.I.G. Capital Acquires Taconic Biosciences

February 7, 2019

Healthcare Services

H.I.G. Capital, through an affiliate, has completed the acquisition of Taconic Biosciences, a global provider of genetically engineered research models and related services. The private equity investment will partner with Taconic's management to support geographic expansion, broaden product and service offerings, and accelerate M&A-driven growth.